| |
October 25, 2012
AET BioTech and
BioXpress Therapeutics to Co-Develop Biosimilar Adalimumab
READ MORE >
World-Class Biologic Experience
Biosimilar biologics are complex
protein structures. The highly experienced BioXpress
Therapeutics team has worked on the development of 12
originator MAbs currently on the market. BioXpress
Therapeutics has a well-defined biosimilar drug development
program which includes:
>> validated protein sequence
>> analytical assays
>> bioanalytical assays
>> pharmacology studies
>> robust and proven production platform
|
 |
BioXpress Therapeutics
SA is a premier provider of high-quality
biosimilar biologic APIs for unmet need
indications such as cancer, inflammation and
autoimmunity. We have made a commitment to be your
partner of choice for the full development of your
biosimilar biologic API. BioXpress Therapeutics is focused on
developing the highest quality product under strict
European Medicines Agency (EMA) guidelines. We bring
together the world’s top biologic development,
manufacturing and regulatory experts dedicated to
your project.
|
|
Our Philosophy
BioXpress Therapeutics
believes all patients should have access to safe and
high-quality biologic therapeutics at affordable
costs.
Our Mission
BioXpress
Therapeutics’ mission is to develop cost-competitive
biosimilar biologic API (MAb and MAb-like biosimilar drugs) to
the highest EMA safety and quality standards.
|
|
|
